CSBR
Champions Oncology, Inc.
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Champions Oncology (CSBR) Stock: Buy, Sell, or Hold?
$4.65
-0.13 (-2.72%)
▼
5d:
-2.31%
30d:
-3.33%
90d:
-8.19%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (80%)
Quality Score
40/100
Position
OVERSOLD
30-Day Fair Range
$4.74 – $4.91
Position: OVERSOLD
Forward P/E & Valuation
46.5x
CHEAP
vs 55.1x historical avg
Wall Street Target
$12.00
+158.1% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$4.60 / $5.06
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: CSBR shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When CSBR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: CSBR is currently trading at $4.65, which is considered oversold relative to its 30-day fair value range of $4.74 to $4.91. From a valuation perspective, the stock is trading at a discount (Forward PE: 46.5) compared to its historical average (55.1). Remarkably, the market is currently pricing in an annual earnings decline of 5.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CSBR is in a strong downtrend. The price is currently testing key support at $4.60. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.00 (+158.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CSBR is in a strong downtrend. The price is currently testing key support at $4.60. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.00 (+158.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.74 -
$4.91
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Trading Range & Key Levels
30-Day Trading Range
$4.74 -
$4.91
Current vs Trading Range
OVERSOLD
Support Level
$4.60
Resistance Level
$5.06
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 158.1% below Wall St target ($12.00)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
46.50
Wall Street Target
$12.00
(+158.1%)
Revenue Growth (YoY)
8.8%
Earnings Growth (YoY)
-61.1%
Profit Margin
-1.9%
Valuation Discount vs History
-5.5% cheaper
PE vs Historical
46.5 vs 55.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.5%
(market-implied from PE analysis)
1-Year Target
$4.39
(-6%)
2-Year Target
$4.15
(-11%)
3-Year Target
$3.92
(-16%)
3-Yr Target (if PE normalizes)
(PE: 47→55)
$4.65
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 46.5, Growth: -16.7%)
$3.39
(+-27%)
Base:
(SPY PE: 19.9, Growth: -16.7%)
$1.45
(-69%)
Bear:
(PE: 16.9, Growth: -16.7%)
$1.23
(-74%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 46.5 to 55.1
Stabilization Target:
$5.51
(+18.5%)
PE Expansion Potential:
+18.5%
Share CSBR Analysis
Share this live CSBR analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (CSBR)
Bullish
2 Retail Mentions
StockTwits Volume
2 msgs
24h retail stream
Last Tracked
Mar 13, 2026
Daily AI digest
AI Retail Discussion Summary:
Champions Oncology ($CSBR) reported revenue of $16.6M in their latest financial update, causing bullish sentiment to surge on StockTwits.
Key Retail Themes:
Financial Performance
Bullish Sentiment
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 5:44 AM ET
Data refreshes hourly during market hours. Next update: 6:44 AM
Data refreshes hourly during market hours. Next update: 6:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSBR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
25 analysts |
$261 | 38 SELL |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 41 HOLD |
|
ABVX
Abivax SA American Depos… |
STRONG BUY
12 analysts |
$164 | 64 BUY |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 42 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$35 | 58 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive CSBR Research Pages
